CA2684242C - Somatic cell reprogramming - Google Patents
Somatic cell reprogramming Download PDFInfo
- Publication number
- CA2684242C CA2684242C CA2684242A CA2684242A CA2684242C CA 2684242 C CA2684242 C CA 2684242C CA 2684242 A CA2684242 A CA 2684242A CA 2684242 A CA2684242 A CA 2684242A CA 2684242 C CA2684242 C CA 2684242C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell
- potency
- pluripotent
- determining factors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001082 somatic cell Anatomy 0.000 title claims abstract description 101
- 230000008672 reprogramming Effects 0.000 title claims abstract description 69
- 210000004027 cell Anatomy 0.000 claims abstract description 493
- 238000000034 method Methods 0.000 claims abstract description 67
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 53
- 239000013598 vector Substances 0.000 claims description 49
- 101150111214 lin-28 gene Proteins 0.000 claims description 40
- 239000013612 plasmid Substances 0.000 claims description 15
- 230000004069 differentiation Effects 0.000 claims description 14
- 210000000130 stem cell Anatomy 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 8
- 206010043276 Teratoma Diseases 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 230000001177 retroviral effect Effects 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 239000002771 cell marker Substances 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 claims 1
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 75
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 72
- 230000014509 gene expression Effects 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 44
- 238000010361 transduction Methods 0.000 description 42
- 230000026683 transduction Effects 0.000 description 37
- 239000002609 medium Substances 0.000 description 27
- 241000288906 Primates Species 0.000 description 21
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 20
- 108700019146 Transgenes Proteins 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 210000002950 fibroblast Anatomy 0.000 description 17
- 239000003550 marker Substances 0.000 description 16
- -1 Rexl Proteins 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 10
- 241000713666 Lentivirus Species 0.000 description 9
- 229920002301 cellulose acetate Polymers 0.000 description 9
- 238000003501 co-culture Methods 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
- 210000001654 germ layer Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 210000000805 cytoplasm Anatomy 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 210000004927 skin cell Anatomy 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 6
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 6
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 6
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 6
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108010082117 matrigel Proteins 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 239000012679 serum free medium Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 102000003896 Myeloperoxidases Human genes 0.000 description 5
- 108090000235 Myeloperoxidases Proteins 0.000 description 5
- 241000862969 Stella Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102100022464 5'-nucleotidase Human genes 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 4
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 4
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 4
- 102100025304 Integrin beta-1 Human genes 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000004754 hybrid cell Anatomy 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000003196 serial analysis of gene expression Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102100036949 Developmental pluripotency-associated protein 2 Human genes 0.000 description 3
- 101000804948 Homo sapiens Developmental pluripotency-associated protein 2 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 3
- 101000784538 Homo sapiens Zinc finger and SCAN domain-containing protein 10 Proteins 0.000 description 3
- 108010025815 Kanamycin Kinase Proteins 0.000 description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 101150001847 Sox15 gene Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 101710101305 Transducin-like enhancer protein 1 Proteins 0.000 description 3
- 102100039362 Transducin-like enhancer protein 1 Human genes 0.000 description 3
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 3
- 101001029301 Xenopus tropicalis Forkhead box protein D3 Proteins 0.000 description 3
- 102100020919 Zinc finger and SCAN domain-containing protein 10 Human genes 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- 210000001900 endoderm Anatomy 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 108010068425 Octamer Transcription Factor-3 Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 231100001160 nonlethal Toxicity 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100029761 Cadherin-5 Human genes 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- 241000440351 Caprine lentivirus Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 description 1
- 101000881866 Homo sapiens Developmental pluripotency-associated protein 3 Proteins 0.000 description 1
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001020548 Homo sapiens LIM/homeobox protein Lhx1 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000958865 Homo sapiens Myogenic factor 5 Proteins 0.000 description 1
- 101000958866 Homo sapiens Myogenic factor 6 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101000625859 Homo sapiens T-box transcription factor TBX6 Proteins 0.000 description 1
- 102100036133 LIM/homeobox protein Lhx1 Human genes 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100038380 Myogenic factor 5 Human genes 0.000 description 1
- 102100038379 Myogenic factor 6 Human genes 0.000 description 1
- 108700026371 Nanog Homeobox Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102100023057 Neurofilament light polypeptide Human genes 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102100024751 T-box transcription factor TBX6 Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010048992 Transcription Factor 4 Proteins 0.000 description 1
- 102100023489 Transcription factor 4 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 108010090677 neurofilament protein L Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010469 pro-virus integration Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/605—Nanog
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/608—Lin28
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91968707P | 2007-03-23 | 2007-03-23 | |
| US60/919,687 | 2007-03-23 | ||
| US97498007P | 2007-09-25 | 2007-09-25 | |
| US60/974,980 | 2007-09-25 | ||
| US98905807P | 2007-11-19 | 2007-11-19 | |
| US60/989,058 | 2007-11-19 | ||
| PCT/US2008/057924 WO2008118820A2 (en) | 2007-03-23 | 2008-03-21 | Somatic cell reprogramming |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2684242A1 CA2684242A1 (en) | 2008-10-02 |
| CA2684242C true CA2684242C (en) | 2019-11-12 |
Family
ID=39708430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2684242A Active CA2684242C (en) | 2007-03-23 | 2008-03-21 | Somatic cell reprogramming |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US8440461B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3399025B1 (cg-RX-API-DMAC7.html) |
| JP (6) | JP5813321B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101516833B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101743306A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008231020B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2684242C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3399025T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL200982A (cg-RX-API-DMAC7.html) |
| SG (2) | SG193653A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008118820A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (249)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| EP1885845A2 (en) | 2005-06-01 | 2008-02-13 | Wisconsin Alumni Research Foundation | Method of forming dendritic cells from embryonic stem cells |
| US8034613B2 (en) | 2005-06-01 | 2011-10-11 | Wisconsin Alumni Research Foundation | Multipotent lymphohematopoietic progenitor cells |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| CN101864392B (zh) | 2005-12-13 | 2016-03-23 | 国立大学法人京都大学 | 核重新编程因子 |
| US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| WO2007095064A2 (en) | 2006-02-09 | 2007-08-23 | Wisconsin Alumni Research Foundation | ERYTHROID CELLS PRODUCING ADULT-TYPE β-HEMOGLOBIN GENERATED FROM HUMAN EMBRYONIC STEM CELLS |
| CA2684242C (en) | 2007-03-23 | 2019-11-12 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
| MX352541B (es) * | 2007-04-07 | 2017-11-29 | Whitehead Inst Biomedical Res | Reprogramación de células somáticas. |
| US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| US20110236971A2 (en) * | 2007-09-25 | 2011-09-29 | Maksym Vodyanyk | Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions |
| AU2008297024B2 (en) * | 2007-10-31 | 2014-08-28 | Kyoto University | Nuclear reprogramming method |
| US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
| AU2008286249B2 (en) | 2007-12-10 | 2013-10-10 | Kyoto University | Efficient method for nuclear reprogramming |
| SG10201400329YA (en) | 2008-05-02 | 2014-05-29 | Univ Kyoto | Method of nuclear reprogramming |
| WO2009137844A2 (en) * | 2008-05-09 | 2009-11-12 | Vistagen Therapeutics, Inc. | Pancreatic endocrine progenitor cells derived from pluripotent stem cells |
| CA2954948A1 (en) * | 2008-06-04 | 2009-12-10 | Cellular Dynamics International, Inc. | Methods for the production of ips cells using non-viral approach |
| CA2969377C (en) | 2008-06-13 | 2019-12-03 | Whitehead Institute For Biomedical Research | Programming and reprogramming of cells |
| CA2695590C (en) | 2008-06-27 | 2018-01-09 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| KR101685209B1 (ko) * | 2008-07-30 | 2016-12-09 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 유도된 다능성 줄기 세포의 효율적인 확립 방법 |
| KR101773345B1 (ko) * | 2008-08-12 | 2017-08-31 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | ｉＰＳ 세포의 생산 방법 |
| WO2010033906A2 (en) * | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| WO2010042800A1 (en) * | 2008-10-10 | 2010-04-15 | Nevada Cancer Institute | Methods of reprogramming somatic cells and methods of use for such cells |
| US8268620B2 (en) * | 2008-10-24 | 2012-09-18 | Wisconsin Alumni Research Foundation | OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells |
| EP2342333A4 (en) * | 2008-10-30 | 2013-05-08 | Univ Kyoto | Method for producing induced pluripotent stem cells |
| WO2010056808A2 (en) * | 2008-11-12 | 2010-05-20 | The Regents Of The University Of California | Compositions and methods for re-programming and re-differentiating cells |
| US9045737B2 (en) * | 2008-12-13 | 2015-06-02 | Dnamicroarray, Inc. | Artificial three-dimensional microenvironment niche culture |
| US20110300627A1 (en) * | 2009-01-20 | 2011-12-08 | Sing George L | Dedifferentiation and reprogramming of cells |
| CA2753208C (en) | 2009-02-20 | 2018-08-21 | Cellular Dynamics International, Inc. | Methods and compositions for the differentiation of stem cells |
| EP2401372A4 (en) * | 2009-02-27 | 2012-09-19 | Univ Kyoto | NEW NUCLEAR REPROGRAMMING SUBSTANCE |
| US9487756B2 (en) | 2009-03-20 | 2016-11-08 | Mesoblast, Inc. | Production of reprogrammed pluripotent cells |
| US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| EP2421957B1 (en) | 2009-04-22 | 2020-11-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| JP5777113B2 (ja) | 2009-05-29 | 2015-09-09 | 学校法人慶應義塾 | 人工多能性幹細胞のクローンの選択方法 |
| DK2548950T3 (en) | 2009-06-05 | 2017-12-11 | Cellular Dynamics Int Inc | Reprogramming of T cells and hematopoietic cells |
| WO2010144696A1 (en) | 2009-06-11 | 2010-12-16 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
| JP5645197B2 (ja) * | 2009-06-23 | 2014-12-24 | 学校法人日本大学 | 幹細胞の未分化状態を維持する新規方法 |
| KR101774206B1 (ko) | 2009-08-07 | 2017-09-04 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 유도된 다능성 줄기 세포의 효율적인 확립 방법 |
| JP5751548B2 (ja) | 2009-08-07 | 2015-07-22 | 国立大学法人京都大学 | イヌｉＰＳ細胞及びその製造方法 |
| JP5709015B2 (ja) | 2009-08-19 | 2015-04-30 | 国立大学法人大阪大学 | 角膜移植用シート |
| US8993329B2 (en) | 2009-09-24 | 2015-03-31 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| GB2474492B (en) * | 2009-10-19 | 2014-05-21 | Tristem Trading Cyprus Ltd | Treatment using reprogrammed mature adult cells |
| US9340772B2 (en) | 2009-10-29 | 2016-05-17 | Mcmaster University | Generating induced pluripotent stem cells and progenitor cells from fibroblasts |
| PL2494035T3 (pl) * | 2009-10-29 | 2018-07-31 | Janssen Biotech, Inc. | Pluripotencjalne komórki macierzyste |
| JP5898086B2 (ja) * | 2009-11-04 | 2016-04-06 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 化学物質を用いるエピソームリプログラミング |
| CN102648274B (zh) | 2009-12-09 | 2013-07-31 | 国立大学法人京都大学 | 包含双呋脒腙的促进多能干细胞分化成心肌细胞的组合物 |
| US20130115622A1 (en) | 2009-12-14 | 2013-05-09 | Kyoto University | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis |
| JP5827220B2 (ja) | 2010-01-22 | 2015-12-02 | 国立大学法人京都大学 | 人工多能性幹細胞の樹立効率改善方法 |
| WO2011102531A1 (en) | 2010-02-16 | 2011-08-25 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| CN102190731B (zh) * | 2010-03-09 | 2016-01-27 | 中国科学院上海生命科学研究院 | 用人工转录因子诱导产生多能干细胞 |
| EP2547768B1 (en) | 2010-03-17 | 2015-12-30 | Association Institut de Myologie | Modified u7 snrnas for treatment of neuromuscular diseases |
| CN102822333A (zh) * | 2010-03-23 | 2012-12-12 | 奥林巴斯株式会社 | 监控干细胞的分化状态的方法 |
| CA2796616A1 (en) | 2010-04-21 | 2011-10-27 | Research Development Foundation | Methods and compositions related to dopaminergic neuronal cells |
| US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| CN106381280B (zh) * | 2010-05-13 | 2020-08-04 | 加州大学董事会 | 用于诱导人类多能干细胞的方法和组合物 |
| US8932857B2 (en) | 2010-06-15 | 2015-01-13 | Kyoto University | Method for selecting reduced differentiation resistance human induced pluripotent stem cells |
| EP2582794B2 (en) | 2010-06-15 | 2024-04-24 | FUJIFILM Cellular Dynamics, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| WO2012020687A1 (en) | 2010-08-13 | 2012-02-16 | Kyoto University | Method of inducing differentiation from pluripotent stem cells to germ cells |
| CN103168236B (zh) | 2010-08-23 | 2016-01-20 | 哈佛大学管理委员会 | 用于膜电位测定的光遗传学探针 |
| CN103209968B (zh) | 2010-08-26 | 2015-08-05 | 国立大学法人京都大学 | 多能干细胞心肌细胞分化促进剂 |
| US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
| US9856210B2 (en) | 2010-09-02 | 2018-01-02 | Kyoto University | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis |
| US9447408B2 (en) | 2010-09-14 | 2016-09-20 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| JP2013545439A (ja) | 2010-09-17 | 2013-12-26 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 多能性幹細胞の有用性および安全性の特徴決定を行うための機能的ゲノミクスアッセイ |
| US9732128B2 (en) | 2010-10-22 | 2017-08-15 | Biotime, Inc. | Methods of modifying transcriptional regulatory networks in stem cells |
| EP2647699B1 (en) | 2010-12-03 | 2020-04-01 | Kyoto University | Efficient method for establishing induced pluripotent stem cells |
| EP2665811B1 (en) | 2011-01-19 | 2017-10-18 | The Regents of The University of California | Somatic cells with innate potential for pluripotency |
| WO2012098260A1 (en) | 2011-01-21 | 2012-07-26 | Axiogenesis Ag | A non-viral system for the generation of induced pluripotent stem (ips) cells |
| WO2012137970A1 (ja) | 2011-04-08 | 2012-10-11 | 国立大学法人大阪大学 | 改変ラミニンおよびその利用 |
| WO2012141181A1 (ja) * | 2011-04-11 | 2012-10-18 | 国立大学法人京都大学 | 核初期化物質 |
| US9133266B2 (en) | 2011-05-06 | 2015-09-15 | Wisconsin Alumni Research Foundation | Vitronectin-derived cell culture substrate and uses thereof |
| CN103703130A (zh) | 2011-07-25 | 2014-04-02 | 国立大学法人京都大学 | 筛选诱导的多能干细胞的方法 |
| WO2013028702A1 (en) * | 2011-08-22 | 2013-02-28 | Mayo Foundation For Medical Education And Research | Methods and materials for obtaining induced pluripotent stem cells |
| WO2013028684A1 (en) | 2011-08-23 | 2013-02-28 | Wisconsin Alumni Research Foundation | Angiohematopoietic progenitor cells |
| US20130274184A1 (en) * | 2011-10-11 | 2013-10-17 | The Trustees Of Columbia University In The City Of New York | Er stress relievers in beta cell protection |
| US20140248698A1 (en) | 2011-10-21 | 2014-09-04 | Arkray, Inc. | Method for culturing pluripotency-maintained singly dispersed cells by means of laminar flow |
| GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
| US20140329317A1 (en) | 2011-11-25 | 2014-11-06 | Kyoto University | Method for culturing pluripotent stem cell |
| WO2013082268A1 (en) * | 2011-11-30 | 2013-06-06 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for regulation of cell aging, carcinogenesis, and reprogramming |
| US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| CA2858148C (en) | 2011-12-05 | 2023-03-14 | Factor Bioscience Inc. | Methods and products for transfecting cells |
| US8497124B2 (en) | 2011-12-05 | 2013-07-30 | Factor Bioscience Inc. | Methods and products for reprogramming cells to a less differentiated state |
| WO2013090919A1 (en) | 2011-12-16 | 2013-06-20 | Wisconsin Alumni Research Foundation | Fgf-2 having enhanced stability |
| WO2013111875A1 (ja) | 2012-01-27 | 2013-08-01 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化誘導法 |
| CA2874259C (en) | 2012-05-23 | 2021-02-09 | Kyoto University | Highly efficient method for establishing induced pluripotent stem cell |
| WO2013184527A1 (en) | 2012-06-05 | 2013-12-12 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
| US9828603B2 (en) | 2012-08-13 | 2017-11-28 | Cedars Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| US9175263B2 (en) | 2012-08-22 | 2015-11-03 | Biotime, Inc. | Methods and compositions for targeting progenitor cell lines |
| WO2014057997A1 (ja) | 2012-10-09 | 2014-04-17 | Hayashi Nakanobu | 初期化ペプチド及びその用途 |
| US10077429B2 (en) | 2012-10-23 | 2018-09-18 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| CA2890110C (en) | 2012-11-01 | 2023-05-02 | Factor Bioscience Inc. | Methods and products for expressing proteins in cells |
| EP2954046B1 (en) | 2013-02-06 | 2025-10-15 | University Of Rochester | Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders |
| EP2955223B1 (en) | 2013-02-08 | 2019-12-18 | Kyoto University | Production methods for megakaryocytes and platelets |
| US9738861B2 (en) | 2013-03-06 | 2017-08-22 | Kyoto University | Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells |
| WO2014136519A1 (ja) | 2013-03-08 | 2014-09-12 | 国立大学法人京都大学 | Ｅｇｆ受容体阻害剤を含む多能性幹細胞の心筋分化促進剤 |
| PL2970912T3 (pl) | 2013-03-13 | 2019-08-30 | Wisconsin Alumni Research Foundation | Sposoby i materiały do hematopoetyczno-śródbłonkowego różnicowania ludzkich pluripotentnych komórek macierzystych w zdefiniowanych warunkach |
| US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
| EP2977449B1 (en) | 2013-03-21 | 2020-02-26 | Kyoto University | Pluripotent stem cell for neuronal differentiation induction |
| EP2980207B1 (en) | 2013-03-25 | 2018-12-05 | Foundation for Biomedical Research and Innovation at Kobe | Cell sorting method |
| JP6461787B2 (ja) | 2013-04-12 | 2019-01-30 | 国立大学法人京都大学 | 肺胞上皮前駆細胞の誘導方法 |
| US9822342B2 (en) | 2013-05-14 | 2017-11-21 | Kyoto University | Method of efficiently inducing cardiomyocytes |
| CN105247041B (zh) | 2013-05-31 | 2018-04-20 | 爱心细胞有限公司 | 组入有水凝胶的层叠细胞膜片 |
| CA2914615C (en) | 2013-06-05 | 2023-10-17 | Biotime, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
| JP6697380B2 (ja) | 2013-06-10 | 2020-05-20 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 多能性幹細胞の有用性および安全性を特徴付けるための初期発生ゲノムアッセイ |
| EP3020803B1 (en) | 2013-06-11 | 2020-03-11 | Kyoto University | Method for producing renal precursor cells |
| US10738323B2 (en) | 2013-07-12 | 2020-08-11 | Cedars-Sinai Medical Center | Generation of induced pluripotent stem cells from normal human mammary epithelial cells |
| EP3031905A4 (en) | 2013-08-07 | 2017-04-26 | Kyoto University | Method for producing pancreatic hormone-producing cell |
| AU2014316100B2 (en) | 2013-09-05 | 2020-11-05 | Eisai R&D Management Co., Ltd. | New method for inducing dopamine-producing neural precursor cells |
| EP3045531B1 (en) | 2013-09-12 | 2023-08-30 | Kaneka Corporation | Method for inducing differentiation of induced pluripotent stem cells and method for selecting induced pluripotent stem cells |
| WO2015037706A1 (ja) | 2013-09-13 | 2015-03-19 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化を促進する化合物 |
| JP6635505B2 (ja) | 2013-11-01 | 2020-01-29 | 国立大学法人京都大学 | 新規軟骨細胞誘導方法 |
| US11767507B2 (en) | 2013-11-08 | 2023-09-26 | The Mclean Hospital Corporation | Methods for efficient generation of GABAergic interneurons from pluripotent stem cells |
| US11377639B2 (en) | 2013-11-15 | 2022-07-05 | Wisconsin Alumni Research Foundation | Lineage reprogramming to induced cardiac progenitor cells (iCPC) by defined factors |
| WO2015087231A1 (en) | 2013-12-11 | 2015-06-18 | Pfizer Limited | Method for producing retinal pigment epithelial cells |
| RU2714404C2 (ru) | 2014-01-31 | 2020-02-14 | Фэктор Байосайенс Инк. | Способы и продукты для получения и доставки нуклеиновых кислот |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| WO2015182765A1 (ja) | 2014-05-30 | 2015-12-03 | 国立大学法人京都大学 | 低分子化合物を用いた多能性幹細胞の心筋分化誘導法 |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| TWI719939B (zh) | 2014-07-14 | 2021-03-01 | 日商中外製藥股份有限公司 | 鑑定蛋白質抗原決定位之方法 |
| CN114292817A (zh) | 2014-07-18 | 2022-04-08 | 国立大学法人京都大学 | 从多能性干细胞诱导细胞免疫治疗用t细胞的方法 |
| EP3194571A4 (en) | 2014-09-18 | 2018-04-18 | North Carolina State University | Mammalian lung spheroids and lung spheroid cells and uses thereof |
| EP3200808B1 (en) | 2014-10-03 | 2024-07-31 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| CA2963934C (en) * | 2014-10-06 | 2023-05-09 | Memorial Sloan-Kettering Cancer Center | Method to reduce oncogenic potential of induced pluripotent stem cells from aged donors |
| DK3233130T3 (da) | 2014-12-17 | 2021-06-21 | Fundacion Para La Investig Medica Aplicada | Nukleinsyrekonstruktioner og genterapivektorer til anvendelse i behandlingen af wilson-sygdom |
| PT3233129T (pt) | 2014-12-17 | 2020-04-15 | Fundacion Para La Investig Medica Aplicada | Construções de ácido nucleico e vetores de terapia génica para utilização no tratamento de doença de wilson e outras condições |
| US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
| SG11201705820UA (en) | 2015-01-16 | 2017-08-30 | Nat Inst Advanced Ind Science & Tech | Gene expression system using stealthy rna, and gene introduction/expression vector including said rna |
| EP3543339A1 (en) | 2015-02-13 | 2019-09-25 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| EP3081638A1 (en) | 2015-04-16 | 2016-10-19 | Kyoto University | Method for producing pseudo-islets |
| US9724432B2 (en) | 2015-04-30 | 2017-08-08 | University Of Rochester | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder |
| AU2016321170B2 (en) | 2015-09-08 | 2022-09-01 | Fujifilm Cellular Dynamics | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells |
| CN108291206B (zh) | 2015-09-08 | 2022-07-08 | 富士胶片细胞动力公司 | 干细胞来源的视网膜色素上皮的基于macs的纯化 |
| CN108350429B (zh) | 2015-10-20 | 2022-02-25 | 富士胶片细胞动力公司 | 用于将多能干细胞定向分化为免疫细胞的方法 |
| CA3005739A1 (en) | 2015-11-18 | 2017-05-26 | Orbis Health Solutions Llc | T7 alpha viral vector system |
| DE102016122317A1 (de) * | 2015-11-24 | 2017-05-24 | Glaxosmithkline Intellectual Property Development Limited | Transientes transfektionsverfahren für retrovirale produktion |
| WO2017100313A1 (en) | 2015-12-07 | 2017-06-15 | Biotime, Inc. | Methods for the re-derivation of diverse pluripotent stem cell-derive brown fat cells |
| US11253551B2 (en) | 2016-01-11 | 2022-02-22 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| WO2017159862A1 (ja) | 2016-03-18 | 2017-09-21 | 国立大学法人京都大学 | 多能性幹細胞由来心筋細胞の凝集体の凍結方法 |
| US11401504B2 (en) | 2016-04-15 | 2022-08-02 | Kyoto University | Method for inducing antigen specific CD8 positive T cells |
| CN109072198B (zh) | 2016-04-22 | 2022-08-26 | 国立大学法人京都大学 | 产多巴胺神经祖细胞的制备方法 |
| EP3455346A1 (en) | 2016-05-12 | 2019-03-20 | Erasmus University Medical Center Rotterdam | A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium |
| WO2017210652A1 (en) | 2016-06-03 | 2017-12-07 | Cedars-Sinai Medical Center | Cdc-derived exosomes for treatment of ventricular tachyarrythmias |
| CN105861447B (zh) * | 2016-06-13 | 2017-12-19 | 广州市搏克生物技术有限公司 | 一种非病毒iPSCs诱导组合物及其试剂盒 |
| US10221395B2 (en) | 2016-06-16 | 2019-03-05 | Cedars-Sinai Medical Center | Efficient method for reprogramming blood to induced pluripotent stem cells |
| US11572545B2 (en) | 2016-06-16 | 2023-02-07 | Cedars-Sinai Medical Center | Efficient method for reprogramming blood to induced pluripotent stem cells |
| CN105936889B (zh) * | 2016-06-24 | 2019-10-18 | 肇庆大华农生物药品有限公司 | 一种ad293球形细胞团的培养方法 |
| CA3029582A1 (en) | 2016-07-01 | 2018-01-04 | Research Development Foundation | Elimination of proliferating cells from stem cell-derived grafts |
| CN116115629A (zh) | 2016-08-17 | 2023-05-16 | 菲克特生物科学股份有限公司 | 核酸产品及其施用方法 |
| US11541078B2 (en) | 2016-09-20 | 2023-01-03 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
| WO2018067826A1 (en) | 2016-10-05 | 2018-04-12 | Cellular Dynamics International, Inc. | Generating mature lineages from induced pluripotent stem cells with mecp2 disruption |
| KR102537361B1 (ko) | 2016-12-27 | 2023-05-26 | 스미또모 가가꾸 가부시키가이샤 | 인공 다능성 줄기 세포의 평가 방법 및 선발 방법, 그리고 인공 다능성 줄기 세포의 제조 방법 |
| JP7136454B2 (ja) | 2017-01-20 | 2022-09-13 | 国立大学法人京都大学 | ＣＤ８α＋β＋細胞傷害性Ｔ細胞の製造方法 |
| US20210130785A1 (en) | 2017-01-26 | 2021-05-06 | Osaka University | Medium for inducing differentiation of stem cells into mesodermal cells and method for producing mesodermal cells |
| WO2018159805A1 (ja) | 2017-03-03 | 2018-09-07 | 国立大学法人京都大学 | 膵前駆細胞の製造方法 |
| US11559548B2 (en) | 2017-03-14 | 2023-01-24 | Kyoto University | Method for producing helper T cells from pluripotent stem cells |
| KR102668891B1 (ko) | 2017-04-18 | 2024-05-29 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 항원-특이적 면역 이펙터 세포 |
| CA3059910A1 (en) | 2017-04-19 | 2018-10-25 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| WO2018209022A2 (en) | 2017-05-10 | 2018-11-15 | University Of Rochester | Methods of treating neuropsychiatric disorders |
| US11821007B2 (en) | 2017-05-25 | 2023-11-21 | Kyoto University | Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell |
| US20200208093A1 (en) | 2017-06-14 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Cell-sealing device |
| EP3643780A4 (en) | 2017-06-19 | 2021-04-07 | Foundation for Biomedical Research and Innovation at Kobe | METHOD FOR PREDICTING THE DIFFERENTIATION CAPACITY OF PLURIPOTENT STEM CELLS, AND ASSOCIATED REAGENT |
| JP6758631B2 (ja) | 2017-06-19 | 2020-09-23 | 国立大学法人大阪大学 | 角膜内皮細胞マーカー及びその利用 |
| US10760057B2 (en) | 2017-07-06 | 2020-09-01 | Wisconsin Alumni Research Foundation | Human pluripotent stem cell-based screening for smooth muscle cell differentiation and disease |
| US11718829B2 (en) * | 2017-07-28 | 2023-08-08 | Breakthrough Tech Llc | Methods and compositions for manufacturing extracellular matrix |
| NL2019517B1 (en) | 2017-09-08 | 2019-03-19 | Univ Erasmus Med Ct Rotterdam | New therapy for Pompe disease |
| US20210363496A1 (en) | 2017-10-17 | 2021-11-25 | Kyoto University | Method for obtaining artificial neuromuscular junction from pluripotent stem cells |
| JP7401432B2 (ja) | 2017-12-01 | 2023-12-19 | エンコーデッド セラピューティクス， インコーポレイテッド | 操作されたｄｎａ結合タンパク質 |
| EP3727351A4 (en) | 2017-12-20 | 2021-10-06 | Cedars-Sinai Medical Center | MANIPULATED EXTRACELLULAR VESICLES FOR ENHANCED RELEASE INTO TISSUE |
| US12146137B2 (en) | 2018-02-05 | 2024-11-19 | Cedars-Sinai Medical Center | Methods for therapeutic use of exosomes and Y-RNAS |
| US20210060210A1 (en) | 2018-03-19 | 2021-03-04 | Kyoto University | Hydrogel capsule |
| KR102848466B1 (ko) | 2018-04-23 | 2025-08-20 | 오리즈루 세라퓨틱스 가부시키가이샤 | 증식 억제제 |
| CA3103663A1 (en) | 2018-06-18 | 2019-12-26 | University Of Rochester | Inhibition of re1-silencing transcription factor in the treatment of schizophrenia and other neuropsychiatric disorders |
| CN112654366A (zh) | 2018-06-21 | 2021-04-13 | 罗切斯特大学 | 治疗或抑制亨廷顿病发作的方法 |
| TW202020145A (zh) | 2018-07-13 | 2020-06-01 | 國立大學法人京都大學 | γδＴ細胞的製造方法 |
| EP3824912A4 (en) | 2018-07-19 | 2022-04-20 | Kyoto University | PLATEFORM CARTILAGE DERIVED FROM PLURIPOTENTS STEM CELLS AND METHODS FOR PRODUCTION OF PLATEFORM CARTILAGE |
| JP7357369B2 (ja) | 2018-07-23 | 2023-10-06 | 国立大学法人京都大学 | 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法 |
| CN112567025B (zh) | 2018-08-10 | 2025-01-17 | 国立大学法人京都大学 | Cd3阳性细胞的制造方法 |
| JP2021535747A (ja) | 2018-09-07 | 2021-12-23 | ウィスコンシン アラムニ リサーチ ファンデーション | ヒト多能性幹細胞からの造血前駆細胞の生成 |
| EP3863682B1 (en) | 2018-10-12 | 2023-05-17 | Vivet Therapeutics | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) |
| MX2021005435A (es) | 2018-11-07 | 2021-09-08 | Vivet Therapeutics | Transgen abcb11 con codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 2 (pfic2). |
| CA3118936A1 (en) | 2018-11-16 | 2020-05-22 | Encoded Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
| WO2020102715A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Method for t cell de-differentiation and resulting cells |
| CA3119599A1 (en) | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Als treatment using induced regulatory t (itreg) cells |
| KR20210096638A (ko) | 2018-11-28 | 2021-08-05 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 억제성 환경에 대한 기능 및 내성을 증진시키기 위한 면역 세포의 멀티플렉스 게놈 편집 |
| MX2021006393A (es) | 2018-11-29 | 2021-10-13 | Univ Texas | Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas. |
| JP7016102B2 (ja) | 2018-12-06 | 2022-02-04 | キリンホールディングス株式会社 | Ｔ細胞又はｎｋ細胞の製造方法、ｔ細胞又はｎｋ細胞の培養用培地、ｔ細胞又はｎｋ細胞の培養方法、未分化ｔ細胞の未分化状態を維持する方法及びｔ細胞又はｎｋ細胞の増殖促進剤 |
| EP3894556A1 (en) | 2018-12-11 | 2021-10-20 | University of Rochester | Methods of treating schizophrenia and other neuropsychiatric disorders |
| WO2020130147A1 (ja) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物 |
| CN113226475A (zh) | 2018-12-26 | 2021-08-06 | 麒麟控股株式会社 | 改造tcr及其制造方法 |
| EP3923962A2 (en) | 2019-02-13 | 2021-12-22 | University of Rochester | Gene networks that mediate remyelination of the human brain |
| US20220145255A1 (en) | 2019-02-26 | 2022-05-12 | Tohoku University | Method for producing osteoblast cluster using ips cells |
| WO2020230832A1 (ja) | 2019-05-15 | 2020-11-19 | 味の素株式会社 | 神経堤細胞または角膜上皮細胞の純化方法 |
| WO2020235319A1 (ja) | 2019-05-20 | 2020-11-26 | 味の素株式会社 | 軟骨又は骨の前駆細胞の拡大培養方法 |
| MX2021014460A (es) | 2019-05-29 | 2022-02-11 | Encoded Therapeutics Inc | Composiciones y metodos para la regulacion genica selectiva. |
| CN119569589A (zh) | 2019-07-03 | 2025-03-07 | 菲克特生物科学股份有限公司 | 阳离子脂质及其用途 |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| WO2021117886A1 (ja) | 2019-12-12 | 2021-06-17 | 国立大学法人千葉大学 | 巨核球および血小板を含む凍結乾燥製剤 |
| EP4110904A1 (en) | 2020-02-28 | 2023-01-04 | Takeda Pharmaceutical Company Limited | Method for producing natural killer cells from pluripotent stem cells |
| EP4130253A4 (en) | 2020-03-31 | 2024-05-29 | Kyoto University | METHOD FOR PRODUCING T-LYMPHOCYTE PROGENITORS |
| WO2021241658A1 (ja) | 2020-05-26 | 2021-12-02 | 株式会社ヘリオス | 低免疫原性細胞 |
| EP3922431A1 (en) | 2020-06-08 | 2021-12-15 | Erasmus University Medical Center Rotterdam | Method of manufacturing microdevices for lab-on-chip applications |
| CN115885038A (zh) | 2020-06-17 | 2023-03-31 | 国立大学法人京都大学 | 表达嵌合抗原受体的免疫活性细胞 |
| EP4180516A4 (en) | 2020-07-13 | 2024-01-17 | Kyoto University | SKELETON MUSCLE PRECURSOR CELLS AND METHOD FOR PURIFICATION THEREOF, COMPOSITION FOR THE TREATMENT OF MYOGENIC DISEASES AND METHOD FOR PRODUCING SKELETON MUSCLE PRECURSOR CELLS CONTAINING CELL GROUPS |
| WO2022019152A1 (ja) | 2020-07-20 | 2022-01-27 | 学校法人 愛知医科大学 | 多能性細胞の未分化維持培養用組成物、多能性細胞の未分化維持培養用培地、多能性細胞の未分化状態での維持培養方法、および多能性細胞の製造方法 |
| US20230265456A1 (en) | 2020-08-10 | 2023-08-24 | Fundacion Para La Investigacion Medica Aplicada | Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis |
| US20240271088A1 (en) | 2020-08-18 | 2024-08-15 | Kyoto University | Method for maintaining and amplifying human primordial germ cells / human primordial germ cell-like cells |
| JPWO2022050419A1 (cg-RX-API-DMAC7.html) | 2020-09-04 | 2022-03-10 | ||
| US20230272433A1 (en) | 2020-09-29 | 2023-08-31 | Genethon | Enhancing Utrophin Expression in Cell by Inducing Mutations Within Utrophin Regulatory Elements and Therapeutic Use Thereof |
| US20230051406A1 (en) | 2020-11-13 | 2023-02-16 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| KR20230125806A (ko) | 2020-12-16 | 2023-08-29 | 우니베르시타트 폼페우 파브라 | 선천성 근이영양증의 치료를 위한 치료용 lama2 페이로드 |
| WO2022136616A1 (en) | 2020-12-23 | 2022-06-30 | Vivet Therapeutics | Minimal bile acid inducible promoters for gene therapy |
| US20240182858A1 (en) | 2021-03-17 | 2024-06-06 | Astellas Pharma Inc. | Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein |
| AU2022255166A1 (en) | 2021-04-07 | 2023-09-28 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
| IL307358A (en) | 2021-04-07 | 2023-11-01 | Century Therapeutics Inc | Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells |
| AU2022266430A1 (en) | 2021-04-30 | 2023-12-14 | Riken | Cord-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said cord-like aggregates |
| EP4349968A1 (en) | 2021-06-04 | 2024-04-10 | Kirin Holdings Kabushiki Kaisha | Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition |
| WO2022259721A1 (ja) | 2021-06-10 | 2022-12-15 | 味の素株式会社 | 間葉系幹細胞の製造方法 |
| AR126145A1 (es) | 2021-06-15 | 2023-09-13 | Takeda Pharmaceuticals Co | Método para producir linfocitos citolíticos naturales a partir de células madre pluripotentes |
| WO2023286834A1 (ja) | 2021-07-15 | 2023-01-19 | アステラス製薬株式会社 | 血管内皮増殖因子（ｖｅｇｆ）高発現ペリサイト様細胞 |
| EP4372079A4 (en) | 2021-07-15 | 2025-07-30 | Astellas Pharma Inc | PERICYTE-LIKE CELLS EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AT A HIGH LEVEL |
| US20250084373A1 (en) | 2021-07-21 | 2025-03-13 | Kyoto University | Method of producing retinal tissue |
| WO2023017848A1 (ja) | 2021-08-11 | 2023-02-16 | 国立大学法人京都大学 | 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法 |
| JP2024531682A (ja) | 2021-09-13 | 2024-08-29 | フジフィルム セルラー ダイナミクス，インコーポレイテッド | コミットされた心臓始原細胞の製造方法 |
| US20240400622A1 (en) | 2021-09-23 | 2024-12-05 | President And Fellows Of Harvard College | Genetically encoded voltage indicators and uses thereof |
| WO2023053220A1 (ja) | 2021-09-28 | 2023-04-06 | 公益財団法人京都大学ｉＰＳ細胞研究財団 | 多能性幹細胞の製造方法 |
| US20230123017A1 (en) * | 2021-10-18 | 2023-04-20 | Wisconsin Alumni Research Foundation | Systems and methods for label-free tracking of human somatic cell reprogramming |
| EP4419665A1 (en) | 2021-10-20 | 2024-08-28 | University of Rochester | Rejuvenation treatment of age-related white matter loss |
| CA3235105A1 (en) | 2021-10-20 | 2023-04-27 | Steven A. Goldman | Humanized chimeras for the prospective assessment of glial cell addition or replacement therapy |
| JP2024539140A (ja) | 2021-10-20 | 2024-10-28 | ユニヴァーシティ オヴ ロチェスター | グリア前駆細胞を若返らせるための方法及び若返ったグリア前駆細胞それ自体 |
| CA3236365A1 (en) | 2021-11-02 | 2023-05-11 | University Of Rochester | Tcf7l2 mediated remyelination in the brain |
| JPWO2023085356A1 (cg-RX-API-DMAC7.html) | 2021-11-11 | 2023-05-19 | ||
| WO2023150557A1 (en) | 2022-02-01 | 2023-08-10 | University Of Rochester | Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods |
| WO2023153464A1 (ja) | 2022-02-09 | 2023-08-17 | 住友ファーマ株式会社 | 多能性幹細胞から中脳底板領域の神経系細胞への分化における、培養液中の細胞の分化能を判定する方法 |
| EP4516905A1 (en) | 2022-04-27 | 2025-03-05 | Kyoto University | Epicardial cell regeneration promoter and method for promoting epicardial cell regeneration |
| EP4518876A1 (en) | 2022-05-05 | 2025-03-12 | University of Rochester | Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease |
| CA3257424A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Genetically modified cells expressing variants of CD16 and NKG2D and their uses |
| JPWO2023238932A1 (cg-RX-API-DMAC7.html) | 2022-06-10 | 2023-12-14 | ||
| WO2024024551A1 (ja) | 2022-07-26 | 2024-02-01 | 国立大学法人京都大学 | シェディング構造を有する人工受容体 |
| EP4594471A1 (en) | 2022-09-30 | 2025-08-06 | Fujifilm Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
| CN120897992A (zh) | 2023-01-23 | 2025-11-04 | 瑞克生乐有限公司 | 视网膜组织的生产方法 |
| EP4658294A2 (en) | 2023-02-02 | 2025-12-10 | University of Rochester | Competitive replacement of glial cells |
| WO2024248017A1 (ja) | 2023-05-29 | 2024-12-05 | 国立研究開発法人理化学研究所 | 心筋細胞を成熟させる方法及び成熟した心筋細胞の製造方法 |
| WO2024248023A1 (ja) | 2023-05-29 | 2024-12-05 | 京都府公立大学法人 | 視交叉上核オルガノイドの製造方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| DE19910044A1 (de) * | 1999-03-08 | 2000-09-14 | Bodo Plachter | Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff |
| US20040199935A1 (en) * | 1999-06-30 | 2004-10-07 | Chapman Karen B. | Cytoplasmic transfer to de-differentiate recipient cells |
| AU6842001A (en) * | 2000-06-15 | 2001-12-24 | Tanja Dominko | Pluripotent mammalian cells |
| US20040235173A1 (en) | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
| US20020136709A1 (en) * | 2000-12-12 | 2002-09-26 | Nucleus Remodeling, Inc. | In vitro-derived adult pluripotent stem cells and uses therefor |
| EP1368465B1 (en) * | 2001-02-21 | 2010-11-17 | The Wistar Institute Of Anatomy And Biology | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| WO2003018780A1 (en) * | 2001-08-27 | 2003-03-06 | Advanced Cell Technology, Inc. | De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
| JP2004248505A (ja) * | 2001-09-21 | 2004-09-09 | Norio Nakatsuji | 移植抗原の一部または全てを欠除したｅｓ細胞由来の未分化な体細胞融合細胞およびその製造 |
| ITMI20012110A1 (it) | 2001-10-12 | 2003-04-12 | Keryos Spa | Vettori multi-cistronici utilizzabili in protocolli di trsferimento genico |
| EP1468094A4 (en) | 2001-12-24 | 2005-01-26 | Es Cell Int Pte Ltd | METHOD OF TRANSDUCTING ES CELLS |
| GB0202149D0 (en) | 2002-01-30 | 2002-03-20 | Univ Edinburgh | Pluripotency determining factors and uses thereof |
| GB0206357D0 (en) | 2002-03-18 | 2002-05-01 | Univ Bath | Cells |
| JP5570677B2 (ja) * | 2002-04-25 | 2014-08-13 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | α−ガラクトシダーゼＡ欠損症の治療 |
| PT2457999T (pt) * | 2002-12-16 | 2019-01-28 | Technion Res & Dev Foundation | Sistema de cultura para células estaminais pluripotentes |
| US20060128018A1 (en) | 2003-02-07 | 2006-06-15 | Zwaka Thomas P | Directed genetic modifications of human stem cells |
| US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
| US7638331B2 (en) * | 2004-01-02 | 2009-12-29 | The Administration of the Tulane Rducation Fund | Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery |
| JP4901471B2 (ja) * | 2004-02-19 | 2012-03-21 | 国立大学法人京都大学 | 体細胞核初期化物質のスクリーニング方法 |
| EP1730261A4 (en) * | 2004-03-10 | 2007-11-28 | Univ California | COMPOSITIONS AND METHODS FOR GROWING EMBRYONIC STEM CELLS |
| KR100484653B1 (ko) | 2004-05-06 | 2005-04-20 | 주식회사 대웅 | 원핵세포에서 활성형의 가용성 단백질을 제조하는 방법 및 이를 위한 폴리시스트론 벡터 |
| US7465580B2 (en) | 2004-05-19 | 2008-12-16 | Wisconsin Alumni Research Foundation | Non-cytotoxic oriP replicon |
| JP2008502644A (ja) | 2004-06-18 | 2008-01-31 | グラクソ グループ リミテッド | ヒスタミンｈ３アンタゴニストとしての３−シクロアルキルベンズアゼピン |
| US7566548B2 (en) * | 2004-08-13 | 2009-07-28 | University Of Massachusetts | Methods for identifying therapeutic agents and for treating disease |
| ES2933478T3 (es) * | 2005-08-03 | 2023-02-09 | Astellas Inst For Regenerative Medicine | Métodos mejorados de reprogramación de células somáticas animales |
| KR20080056181A (ko) | 2005-09-02 | 2008-06-20 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 전구세포주의 유도 방법 |
| US20070087437A1 (en) | 2005-10-14 | 2007-04-19 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| CN101864392B (zh) | 2005-12-13 | 2016-03-23 | 国立大学法人京都大学 | 核重新编程因子 |
| JP4803584B2 (ja) | 2006-02-08 | 2011-10-26 | 独立行政法人産業技術総合研究所 | 脂質生産性の高い形質転換微生物 |
| CA2658204A1 (en) | 2006-07-07 | 2008-01-31 | Kyowa Hakko Kirin Co., Ltd. | Human artificial chromosome (hac) vector and human cell medicine comprising same |
| WO2008013737A2 (en) | 2006-07-19 | 2008-01-31 | University Of Florida Research Foundation, Inc. | Compositions for reprogramming a cell and uses therefor |
| EP2054506A1 (en) | 2006-08-15 | 2009-05-06 | Agency for Science, Technology and Research | Mesenchymal stem cell conditioned medium |
| EP2053128A4 (en) | 2006-08-15 | 2010-05-05 | Ishihara Sangyo Kaisha | INNOVATIVE METHOD OF USING MICROBIAL MUTANT |
| JP2008067693A (ja) | 2006-08-15 | 2008-03-27 | Ishihara Sangyo Kaisha Ltd | 微生物変異体の新規利用方法 |
| WO2008033469A1 (en) | 2006-09-15 | 2008-03-20 | Children's Medical Center Corporation | Methods for producing embryonic stem cells from parthenogenetic embryos |
| CA2684242C (en) | 2007-03-23 | 2019-11-12 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
| CA2725953A1 (en) | 2007-05-29 | 2008-12-11 | Christopher B. Reid | Methods for production and uses of multipotent cell populations, pluripotent cell populations, neuronal cell populations, and muscle cell populations |
| JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| WO2009032456A2 (en) | 2007-08-01 | 2009-03-12 | Primegen Biotech Llc | Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state |
| WO2009032194A1 (en) | 2007-08-31 | 2009-03-12 | Whitehead Institute For Biomedical Research | Wnt pathway stimulation in reprogramming somatic cells |
| US7615374B2 (en) | 2007-09-25 | 2009-11-10 | Wisconsin Alumni Research Foundation | Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions |
| US20110236971A2 (en) | 2007-09-25 | 2011-09-29 | Maksym Vodyanyk | Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions |
| WO2009058712A1 (en) * | 2007-10-29 | 2009-05-07 | Trustees Of Dartmouth College | Toxoplasma gondii mutant with enhanced homologous recombination and uses thereof |
| AU2008297024B2 (en) | 2007-10-31 | 2014-08-28 | Kyoto University | Nuclear reprogramming method |
| WO2009061442A1 (en) * | 2007-11-06 | 2009-05-14 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells |
| US9005966B2 (en) | 2007-11-19 | 2015-04-14 | The Regents Of The University Of California | Generation of pluripotent cells from fibroblasts |
| EP2072618A1 (en) | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
| US9206439B2 (en) | 2008-01-14 | 2015-12-08 | Wisconsin Alumni Research Foundation | Efficient oriP/EBNA-1 plasmid vector |
| WO2009092042A1 (en) | 2008-01-18 | 2009-07-23 | Nevada Cancer Institute | Reprogramming of differentiated progenitor or somatic cells using homologous recombination |
| WO2009102983A2 (en) * | 2008-02-15 | 2009-08-20 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| SG10201400329YA (en) | 2008-05-02 | 2014-05-29 | Univ Kyoto | Method of nuclear reprogramming |
| CA2954948A1 (en) | 2008-06-04 | 2009-12-10 | Cellular Dynamics International, Inc. | Methods for the production of ips cells using non-viral approach |
| WO2010012077A1 (en) | 2008-07-28 | 2010-02-04 | Mount Sinai Hospital | Compositions, methods and kits for reprogramming somatic cells |
| KR101773345B1 (ko) | 2008-08-12 | 2017-08-31 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | ｉＰＳ 세포의 생산 방법 |
| WO2010028019A2 (en) | 2008-09-03 | 2010-03-11 | The General Hospital Corporation | Direct reprogramming of somatic cells using non-integrating vectors |
| US8268620B2 (en) | 2008-10-24 | 2012-09-18 | Wisconsin Alumni Research Foundation | OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells |
-
2008
- 2008-03-21 CA CA2684242A patent/CA2684242C/en active Active
- 2008-03-21 US US12/053,440 patent/US8440461B2/en active Active
- 2008-03-21 JP JP2010501136A patent/JP5813321B2/ja active Active
- 2008-03-21 CN CN200880014084A patent/CN101743306A/zh active Pending
- 2008-03-21 WO PCT/US2008/057924 patent/WO2008118820A2/en not_active Ceased
- 2008-03-21 AU AU2008231020A patent/AU2008231020B2/en active Active
- 2008-03-21 EP EP18177810.1A patent/EP3399025B1/en active Active
- 2008-03-21 KR KR1020097022090A patent/KR101516833B1/ko active Active
- 2008-03-21 SG SG2012019428A patent/SG193653A1/en unknown
- 2008-03-21 SG SG2012019410A patent/SG193652A1/en unknown
- 2008-03-21 DK DK18177810.1T patent/DK3399025T3/da active
- 2008-03-21 EP EP08744218A patent/EP2137296A2/en not_active Withdrawn
-
2009
- 2009-09-16 IL IL200982A patent/IL200982A/en active IP Right Grant
-
2010
- 2010-03-18 US US12/727,061 patent/US8183038B2/en active Active
-
2013
- 2013-02-13 US US13/766,100 patent/US9499786B2/en active Active
- 2013-03-11 US US13/793,594 patent/US10106772B2/en active Active
-
2015
- 2015-05-01 JP JP2015094203A patent/JP6788329B2/ja active Active
-
2018
- 2018-08-06 JP JP2018147683A patent/JP6924732B2/ja active Active
- 2018-08-06 JP JP2018147684A patent/JP2018183183A/ja active Pending
- 2018-09-21 US US16/137,899 patent/US20190106675A1/en not_active Abandoned
-
2020
- 2020-03-13 US US16/818,958 patent/US11898162B2/en active Active
-
2021
- 2021-08-02 JP JP2021126772A patent/JP2021176331A/ja active Pending
-
2024
- 2024-01-04 US US18/404,213 patent/US20240271087A1/en active Pending
- 2024-01-29 JP JP2024010931A patent/JP2024038501A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240271087A1 (en) | Somatic Cell Reprogramming | |
| EP2476750A1 (en) | Somatic cell reprogramming | |
| US10221396B2 (en) | Reprogramming T cells and hematopoietic cells | |
| CN102190731B (zh) | 用人工转录因子诱导产生多能干细胞 | |
| US20190330654A1 (en) | Pluripotent stem cells obtained by non-viral reprogramming | |
| AU2008360135A1 (en) | Efficient method for establishing induced pluripotent stem cells | |
| HK1247640A1 (zh) | 高品质ips细胞的制造方法 | |
| AU2015200413B2 (en) | Reprogramming t cells and hematopoietic cells | |
| WO2010131747A1 (ja) | ウイルス産生細胞 | |
| AU2016200360B2 (en) | Somatic cell reprogramming | |
| AU2013267048B2 (en) | Somatic cell reprogramming | |
| HK1172057A (en) | Somatic cell reprogramming |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130318 |